S1P Receptor Modulator Therapy for Ulcerative Colitis: Starting and Monitoring
Written by: CDHF
Updated: September 16th, 2024
S1P receptor modulator therapy has emerged as a promising treatment option for managing ulcerative colitis (UC). If you read our other article on understanding S1P Receptor Modulator Therapy for UC, you’ll know all about how it works, and its potential benefits for those with UC. To summarize, S1P receptor modulators are medications intended to assist in the management of autoimmune and inflammatory conditions like ulcerative colitis. These medications focus on particular receptors known as sphingosine-1-phosphate (S1P) receptors, located on the surface of different cells, including those within the immune system. By affecting these receptors, S1P modulators aid in controlling immune responses and alleviating inflammation.
This article will provide an overview of the practical aspects of this therapy, including recommended dosages, methods of administration, and important contraindications to ensure safe and effective use. It’s important to discuss this with your healthcare provider.
Dosage
Starting Dosage
Etrasimod (Velsipity™) is given at a standard dose of 2mg a day. Whereas, Ozanimod (Zeposia®) is usually given first as a starter pack with a dose that steadily increases from 0.25mg to the maintenance dose of 1mg per day. The benefits and drawbacks of Etrasimod and Ozanimod appear to be similar.
It’s essential to follow the prescribing healthcare provider’s dosage recommendations and to not alter the dosage without professional guidance.
Administration
Method of Administration
S1P receptor modulators are administered orally in the form of capsules. Here are some key points for administration:
- Consistency: Take the medication at the same time each day to maintain stable levels in the bloodstream.
- With or Without Food: These medications can generally be taken with or without food, but individuals should follow specific instructions provided with their prescription.
- Swallow Whole: Do not crush, chew, or split the capsules, as this could affect the release and absorption of the medication.
Monitoring
Regular monitoring is essential when starting S1P receptor modulator therapy. Healthcare providers typically conduct:
- Heart Rate Monitoring: Because S1P receptor inhibitors can rarely cause bradycardia (or slow heart rate), your doctor will get an EKG (electrocardiogram) before starting an S1P receptor antagonist to make sure you don’t have any underlying condition that can make your hear slow. S1P inhibitors are generally not used in people who have had major heart issues in the last 6 months. Your doctor may ask you to get an EKG 6 hours after your first dose of an S1P receptor modulator to make sure you do not develop bradycardia. It is rare to develop bradycardia later in the course of therapy
- Ophthalmic Examination: If you are over 60 or have diabetes, your doctor may also have you see an ophthalmologist to make sure your retinas (the back of your eyes) are healthy, because S1P inhibitors can rarely cause a conditional called macular edema, or swelling at the back of the eye that can affect vision. Developing macular edema is very rare and is usually reversible, so you should immediately report any blurry vision or visual disturbances that occur while taking an S1P receptor modulator.
- Liver Function Tests: Periodic liver function tests are recommended to detect any liver-related side effects early.
Conclusion
S1P receptor modulator therapy offers a valuable treatment option for managing ulcerative colitis, particularly in patients who have not responded adequately to other therapies. Understanding the appropriate dosage, and method of administration is crucial for maximizing the benefits of this treatment while minimizing potential risks. Always consult with a healthcare provider to ensure this therapy is appropriate for your specific situation and to receive personalized dosing and monitoring instructions.
Part 1:
Part 2:
Part 3:
Part 4:
